Education
About Us
Working with TipRanks
Follow Us
Biosergen AB (DE:8N1)
FRANKFURT:8N1
8N1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.02 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)166.00
Market Cap
€13.20M
Enterprise Value€1.46B
Total Cash (Recent Filing)€50.61M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Aug 28, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding234,823,210
10 Day Avg. Volume500
30 Day Avg. Volume166
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-310.80
Price to Sales (P/S)0.00
P/FCF Ratio-630.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Biosergen AB News
8N1 FAQ
What was Biosergen AB’s price range in the past 12 months?
Biosergen AB lowest stock price was €0.02 and its highest was €0.09 in the past 12 months.
What is Biosergen AB’s market cap?
Biosergen AB’s market cap is €13.20M.
When is Biosergen AB’s upcoming earnings report date?
Biosergen AB’s upcoming earnings report date is Aug 28, 2025 which is in 73 days.
How were Biosergen AB’s earnings last quarter?
Currently, no data Available
Is Biosergen AB overvalued?
According to Wall Street analysts Biosergen AB’s price is currently Overvalued.
Does Biosergen AB pay dividends?
Biosergen AB does not currently pay dividends.
What is Biosergen AB’s EPS estimate?
Biosergen AB’s EPS estimate is >-0.01.
How many shares outstanding does Biosergen AB have?
Biosergen AB has 234,823,210 shares outstanding.
What happened to Biosergen AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biosergen AB?
Currently, no hedge funds are holding shares in DE:8N1
Company Description
Biosergen AB
Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
Technical Analysis
PILA PHARMA AB
―
Biovica International AB Class B
―
Active Biotech AB
―
Spago Nanomedical AB
―
Bio-Works Technologies AB
―